Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Income from Continuing Operations (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Income from Continuing Operations for 11 consecutive years, with 77371000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 218.7% to 77371000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 136826000.0, a 274.75% decrease, with the full-year FY2025 number at 130295000.0, down 68.26% from a year prior.
  • Income from Continuing Operations was 77371000.0 for Q4 2025 at Cartesian Therapeutics, down from 19518000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 14952000.0 in Q2 2024 to a low of 77371000.0 in Q4 2025.
  • A 5-year average of 12304700.0 and a median of 13593000.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 5505.67% in 2022, then crashed 700.58% in 2023.
  • Cartesian Therapeutics' Income from Continuing Operations stood at 12377000.0 in 2021, then crashed by 52.39% to 5893000.0 in 2022, then plummeted by 700.58% to 35392000.0 in 2023, then surged by 31.41% to 24277000.0 in 2024, then tumbled by 218.7% to 77371000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Income from Continuing Operations are 77371000.0 (Q4 2025), 19518000.0 (Q3 2025), and 20063000.0 (Q2 2025).